A crop breeding innovation that uses HEI10 gene overexpression to dramatically increase genetic recombination rates in plants. Validated in Arabidopsis with a 2.7-fold crossover increase, the technology is now being translated into tomato and potentially other crop species to accelerate breeding programs.
This technology leverages the HEI10 gene as a crossover rheostat to overcome one of the most persistent bottlenecks in crop breeding: the limited number of genetic recombination events per plant. By increasing HEI10 expression, researchers can massively elevate crossover rates, generating greater genetic diversity in offspring and enabling faster, more efficient development of improved crop varieties.
The approach addresses a fundamental challenge in plant breeding, where low recombination frequency restricts the combinations of beneficial traits that breeders can select for. By providing a biological switch to boost recombination, this technology can accelerate the introduction of desirable agronomic traits such as disease resistance, drought tolerance, and yield improvements into elite crop lines.
Core mechanism:
Validated performance:
Crop translation strategy:
The technology has reached an advanced stage of validation in the model plant Arabidopsis, with published peer-reviewed evidence demonstrating its effectiveness. Current work represents the critical translation phase into crop species, specifically tomato. Transgenic tomato lines overexpressing HEI10 have been generated in multiple genetic backgrounds and crossed to produce experimental populations. The next phase involves whole-genome sequencing to quantify crossover rates in these crop plants, which will validate whether the dramatic recombination boost observed in Arabidopsis translates to commercial crop species. Success in tomato would establish proof-of-concept for extending this breeding acceleration technology to other major crops.
Cambridge is a collegiate, comprehensive research university that combines broad academic depth with world-class facilities and strong translational activity. Industry engages through co-located labs, a major biomedical campus integrated with an NHS hospital system, and research and technology parks across the Cambridge cluster. Its location in a mature startup and scale-up ecosystem provides ready access to venture funding, prototyping resources, and collaboration with global R&D sites. Research is backed by competitive UKRI council funding and other national sources, with additional support from major charities and European programs. A dedicated technology transfer office supports IP, licensing, and seed investment to accelerate commercialization.